There remains a clinical need to improve health outcomes in patients with ischemic heart
disease (IHD) the leading cause of death and disability in Singapore and worldwide. One
neglected therapeutic target is 'myocardial reperfusion injury' in ST-segment elevation
myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention
(PPCI). This results in microvascular obstruction (MVO) and cardiomyocyte death and
contributes upto 50% of the final myocardial infarct (MI) size. Cangrelor, a potent
intravenous platelet P2Y12 inhibitor with rapid onset and offset of action, has been
demonstrated in experimental animal studies to reduce MI size when administered prior to
reperfusion. Whether Cangrelor given together with Ticagrelor would be more effective at
reducing MI size in STEMI patients treated by PPCI is not known and is investigated in the
Platelet Inhibition to Target Reperfusion Injury (PITRI) trial.
Phase:
Phase 2
Details
Lead Sponsor:
National Heart Centre Singapore
Collaborators:
Khoo Teck Puat Hospital National University Hospital, Singapore Tan Tock Seng Hospital